An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease

References

• ChiaEM, MitchellP, RochtchinaE, LeeAJ, MarounR, WangJJ. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2003;31(3):229–232. doi:10.1046/j.1442-9071.2003.00634.x12786773
   PubMed Web of Science ®Google Scholar
• LinPY, TsaiSY, ChengCY, LiuJH, ChouP, HsuWM. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110(6):1096–1101. doi:10.1016/S0161-6420(03)00262-812799232
   PubMed Web of Science ®Google Scholar
• McCartyCA, BansalAK, LivingstonPM, StanislavskyYL, TaylorHR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105(6):1114–1119. doi:10.1016/S0161-6420(98)96016-X9627665
   PubMed Web of Science ®Google Scholar
• FarrandKF, FridmanM, StillmanIO, SchaumbergDA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98. doi:10.1016/j.ajo.2017.06.03328705660
   PubMed Web of Science ®Google Scholar
• SchaumbergDA, SullivanDA, BuringJE, DanaMR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326. doi:10.1016/s0002-9394(03)00218-612888056
   PubMed Web of Science ®Google Scholar
• CraigJP, NicholsKK, AkpekEK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.00828736335
   PubMed Web of Science ®Google Scholar
• BronAJ, de PaivaCS, ChauhanSK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.01128736340
   PubMed Web of Science ®Google Scholar
• BaudouinC, FigueiredoFC, MessmerEM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520–530. doi:10.5301/EJO.500095228362054
   PubMed Web of Science ®Google Scholar
• SternME. Pathophysiology and allergy of the lacrimal functional unit: what goes wrong with our tear-secreting apparatus. Asian J Ophthalmol. 2005;7(S1):5–8.
   Google Scholar
• JonesL, DownieLE, KorbD, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.00628736343
   PubMed Web of Science ®Google Scholar
• MarshP, PflugfelderSC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106(4):811–816. doi:10.1016/S0161-6420(99)90171-910201607
   PubMed Web of Science ®Google Scholar
• KunertKS, TisdaleAS, SternME, SmithJA, GipsonIK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Archiv Ophthalmol. 2000;118(11):1489–1496. doi:10.1001/archopht.118.11.1489
   PubMedGoogle Scholar
• TurnerK, PflugfelderSC, JiZ, FeuerWJ, SternM, ReisBL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19(4):492–496. doi:10.1097/00003226-200007000-0001810928765
   PubMed Web of Science ®Google Scholar
• GaoJ, SanaR, CalderV, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci. 2013;54(7):4717–4733. doi:10.1167/iovs.13-1168123778874
   PubMed Web of Science ®Google Scholar
• PerryHD, SolomonR, DonnenfeldED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Archiv Ophthalmol. 2008;126(8):1046–1050. doi:10.1001/archopht.126.8.1046
   PubMedGoogle Scholar
• AlvesM, FonsecaEC, AlvesMF, et al. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf. 2013;11(3):181–192. doi:10.1016/j.jtos.2013.02.00223838019
   PubMed Web of Science ®Google Scholar
• SacchettiM, MantelliF, LambiaseA, MastropasquaA, MerloD, BoniniS. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98(8):1016–1022. doi:10.1136/bjophthalmol-2013-30407224344232
   PubMed Web of Science ®Google Scholar
• WanKH, ChenLJ, YoungAL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–225. doi:10.1016/j.jtos.2014.12.00626045239
   PubMed Web of Science ®Google Scholar
• ZhouXQ, WeiRL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea. 2014;33(7):760–767. doi:10.1097/ICO.000000000000012324815112
   PubMed Web of Science ®Google Scholar
• ChangSH, KangYN, ChiuHY, ChiuYH. A systematic review and meta-analysis comparing pigtail catheter and chest tube as the initial treatment for pneumothorax. Chest. 2018;153(5):1201–1212. doi:10.1016/j.chest.2018.01.04829452099
   PubMed Web of Science ®Google Scholar
• KaoCC, LinYS, ChuHC, FangTC, WuMS, KangYN. Association of renal function and direct-acting antiviral agents for HCV: a network meta-analysis. J Clin Med. 2018;7(10). doi:10.3390/jcm7100314
   Web of Science ®Google Scholar
• LinEY, KuoYK, KangYN. Effects of three common lumbar interbody fusion procedures for degenerative disc disease: a network meta-analysis of prospective studies. Int J Surg. 2018;60:224–230. doi:10.1016/j.ijsu.2018.11.00930471365
   PubMed Web of Science ®Google Scholar
• LinTM, ChiJE, ChangCC, KangYN. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials. J Pain Res. 2019;12:83–91. doi:10.2147/JPR.S18600430588082
   PubMed Web of Science ®Google Scholar
• MoherD, LiberatiA, TetzlaffJ, AltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b265119622551
   PubMed Web of Science ®Google Scholar
• AltiparmakUE, AcarDE, OzerPA, et al. Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients. Eye. 2010;24(6):1044–1050. doi:10.1038/eye.2009.24619834507
   PubMed Web of Science ®Google Scholar
• DemiryayE, YaylalV, CetinEN, YldrmC. Effects of topical cyclosporine A plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011;37(5):312–315. doi:10.1097/ICL.0b013e31822563be21792057
   PubMed Web of Science ®Google Scholar
• KimEC, ChoiJS, JooCK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147(2):206–213. doi:10.1016/j.ajo.2008.08.01518848318
   PubMed Web of Science ®Google Scholar
• PerryHD, Doshi-CarnevaleS, DonnenfeldED, SolomonR, BiserSA, BloomAH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25(2):171–175. doi:10.1097/01.ico.0000176611.88579.0a16371776
   PubMed Web of Science ®Google Scholar
• PrabhasawatP, TesavibulN, MahawongW. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea. 2012;31(12):1386–1393. doi:10.1097/ICO.0b013e31823cc09823135530
   PubMed Web of Science ®Google Scholar
• RaoSN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010;26(2):157–163. doi:10.1089/jop.2009.009120415623
   PubMed Web of Science ®Google Scholar
• RaoSN. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. J Ocul Pharmacol Ther. 2011;27(6):603–609. doi:10.1089/jop.2011.007321999340
   PubMed Web of Science ®Google Scholar
• SalibGM, McDonaldMB, SmolekM. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg. 2006;32(5):772–778. doi:10.1016/j.jcrs.2005.10.03416765793
   PubMed Web of Science ®Google Scholar
• SchechterBA, KatzRS, FriedmanLS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26(6):651–659. doi:10.1007/s12325-009-0037-219551353
   PubMed Web of Science ®Google Scholar
• WillenCM, McGwinG, LiuB, OwsleyC, RosenstielC. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens-Sci Clin Pract. 2008;34(1):43–45. doi:10.1097/ICL.0b013e3180676d44
   PubMed Web of Science ®Google Scholar
• WuAH, WangBL, PeiS. Effect of cyclosporin A in the treatment of severe dry eye syndrome. Int J Ophthalmol. 2009;9(2):389–390.
   Google Scholar
• YangXB, CaoFZ. Clinical observation of cyclosporine eye drops with artificial tears for dry eyes. Int Eye Sci. 2016;16(5):923–926.
   Google Scholar
• SullivanBD, CrewsLA, MessmerEM, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol (Copenh). 2014;92(2):161–166. doi:10.1111/aos.12012
   PubMed Web of Science ®Google Scholar
• SallKN, CohenSM, ChristensenMT, SteinJM. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006;32(1):21–26. doi:10.1097/01.icl.0000170599.57728.2916415689
   PubMedGoogle Scholar
• YavuzB, Bozdag PehlivanS, UnluN. An overview on dry eye treatment: approaches for cyclosporin a delivery. Scie World J. 2012;2012:194848. doi:10.1100/2012/194848
   Web of Science ®Google Scholar
• SchwartzLM, WoloshinS. A clear-eyed view of restasis and chronic dry eye disease. JAMA Intern Med. 2018;178(2):181–182. doi:10.1001/jamainternmed.2017.790429297040
   PubMed Web of Science ®Google Scholar
• PariharJKS, JainVK, ChaturvediP, KaushikJ, JainG, PariharAKS. Computer and visual display terminals (VDT) vision syndrome (CVDTS). Med J Armed Forces India. 2016;72(3):270–276. doi:10.1016/j.mjafi.2016.03.01627546968
   PubMedGoogle Scholar
• CourtinR, PereiraB, NaughtonG, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. BMJ Open. 2016;6(1):e009675. doi:10.1136/bmjopen-2015-009675
   PubMed Web of Science ®Google Scholar
• YamadaM, MizunoY, ShigeyasuC. Impact of dry eye on work productivity. Clinico Econ Outcomes Res. 2012;4:307–312. doi:10.2147/CEOR.S36352
   PubMedGoogle Scholar
• LallemandF, Felt-BaeyensO, BesseghirK, Behar-CohenF, GurnyR. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56(3):307–318.14602172
   PubMed Web of Science ®Google Scholar
• LeonardiA, Van SettenG, AmraneM, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296. doi:10.5301/ejo.500077927055414
   PubMed Web of Science ®Google Scholar